Published online Mar 26, 2019. doi: 10.12998/wjcc.v7.i6.734
Peer-review started: December 20, 2018
First decision: January 19, 2019
Revised: February 1, 2019
Accepted: February 18, 2019
Article in press: February 18, 2019
Published online: March 26, 2019
Processing time: 96 Days and 18.7 Hours
Transcatheter device closure of atrial septal defect (ASD) guided by fluoroscopy and/or transesophageal echocardiography is a mature technology. Little study has focused on whether the technology can be guided totally by transthoracic echocardiography (TTE), even in pregnant women with ASD.
To evaluate the safety and efficacy of totally TTE guided transcatheter device closure of ASD in pregnant women.
Six pregnant women (gestational age 20-26 wk) with ASD underwent transcatheter device closure totally guided by TTE at our cardiac center from January 2015 to August 2017. A routine transcatheter procedure without fluoroscopy or intubation and a domestic occluder were used in this study.
All patients had successful closure with good clinical results, and the overall immediate complete closure rate was 100%. The size of the occluder deployed ranged from 20 to 32 mm (26.7 ± 4.3 mm), the procedure time ranged from 30 to 50 min (41.7 ± 7.5 min), and the length of hospital stay was 2-3 d (mean 2.2 ± 0.4 d). There were no serious cardiovascular related complications, and transient arrhythmias occurred in one patient during the procedure. During the follow-up period (3 mo to 2 years), no occluder dislodgement, residual fistulas, or thromboses occurred. All of the patients underwent vaginal delivery between 36 and 38 wk of gestation.
Totally TTE guided transcatheter device closure of ASD in pregnant women may be safe and effective.
Core tip: We want to report our experience about the feasibility and safety of totally transthoracic echocardiography guided transcatheter device closure of atrial septal defect (ASD) in pregnant women. Device closure of ASD guided by fluoroscopy and echocardiography is mature with proven results and remains the preferred treatment option in most of hospitals. But for pregnant women with ASD, our procedure described in this study may be performed as another choice.